WO1999020742A3 - Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv - Google Patents
Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv Download PDFInfo
- Publication number
- WO1999020742A3 WO1999020742A3 PCT/EP1998/006610 EP9806610W WO9920742A3 WO 1999020742 A3 WO1999020742 A3 WO 1999020742A3 EP 9806610 W EP9806610 W EP 9806610W WO 9920742 A3 WO9920742 A3 WO 9920742A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell line
- packaging cell
- line producing
- mlv
- siv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13349/99A AU1334999A (en) | 1997-10-20 | 1998-10-19 | A packaging cell line producing siv-pseudotyped mlv |
EP98956852A EP1025208A2 (fr) | 1997-10-20 | 1998-10-19 | Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK1196/97 | 1997-10-20 | ||
DK119697 | 1997-10-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999020742A2 WO1999020742A2 (fr) | 1999-04-29 |
WO1999020742A3 true WO1999020742A3 (fr) | 1999-07-01 |
Family
ID=8102058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/006610 WO1999020742A2 (fr) | 1997-10-20 | 1998-10-19 | Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1025208A2 (fr) |
AU (1) | AU1334999A (fr) |
WO (1) | WO1999020742A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0817858B1 (fr) | 1995-03-09 | 2003-04-23 | Austrian Nordic Biotherapeutics AG | Vecteurs qui portent des genes therapeutiques codant des peptides antimicrobiens pour la therapie genique |
DE69940521D1 (de) | 1998-10-01 | 2009-04-16 | Univ Southern California | Retrovirales genübertragungssystem und entsprechendes verwendungverfahren |
AU2002218218A1 (en) * | 2000-10-10 | 2002-04-22 | Austrian Nordic Biotherapeutics Ag | A novel system for the evaluation of the activity and/or specificity of a viral component |
WO2008151633A2 (fr) * | 2007-06-15 | 2008-12-18 | Skau Aps | Vecteurs pour un vaccin contre le vih-1 |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
CN105624193B (zh) | 2008-09-26 | 2021-07-13 | 索元生物医药(美国)有限公司 | 重组载体 |
CA2816570A1 (fr) | 2010-10-31 | 2012-05-03 | Tocagen Inc. | Traitement et surveillance ameliores du cancer au moyen de vecteurs recombinants |
JP6419706B2 (ja) | 2012-10-25 | 2018-11-07 | トカジェン インコーポレーテッド | ミニプロモーターカセットを含むレトロウイルスベクター |
US9642921B2 (en) | 2012-12-20 | 2017-05-09 | Tocagen Inc. | Cancer combination therapy and recombinant vectors |
US11279949B2 (en) | 2015-09-04 | 2022-03-22 | Denovo Biopharma Llc | Recombinant vectors comprising 2A peptide |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011524A1 (fr) * | 1992-11-09 | 1994-05-26 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Particules vectorielles pouvant etre ciblees |
WO1997017457A2 (fr) * | 1995-11-08 | 1997-05-15 | Whitehead Institute For Biomedical Research | Lignees cellulaires stables d'encapsidation produisant un retrovirus pseudotype |
WO1998038325A2 (fr) * | 1997-02-27 | 1998-09-03 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4 |
-
1998
- 1998-10-19 EP EP98956852A patent/EP1025208A2/fr not_active Withdrawn
- 1998-10-19 WO PCT/EP1998/006610 patent/WO1999020742A2/fr not_active Application Discontinuation
- 1998-10-19 AU AU13349/99A patent/AU1334999A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011524A1 (fr) * | 1992-11-09 | 1994-05-26 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Particules vectorielles pouvant etre ciblees |
WO1997017457A2 (fr) * | 1995-11-08 | 1997-05-15 | Whitehead Institute For Biomedical Research | Lignees cellulaires stables d'encapsidation produisant un retrovirus pseudotype |
WO1998038325A2 (fr) * | 1997-02-27 | 1998-09-03 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4 |
Non-Patent Citations (8)
Also Published As
Publication number | Publication date |
---|---|
WO1999020742A2 (fr) | 1999-04-29 |
EP1025208A2 (fr) | 2000-08-09 |
AU1334999A (en) | 1999-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992005266A3 (fr) | Cellules d'encapsidation | |
WO1999020742A3 (fr) | Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv | |
CA2223691A1 (fr) | Replication du virus de l'herpes simplex specifique de cellule ou de tumeur | |
CA2182303A1 (fr) | Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire | |
EP0844888A4 (fr) | Vecteurs viraux specifiques a des tissus | |
EP0979101A4 (fr) | ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE | |
WO2003082200A3 (fr) | Virus herpes simplex oncolytique puissant pour une therapie du cancer | |
CA2328404A1 (fr) | Nouvelles cellules lentivirales d'encapsidation | |
WO1996003515A3 (fr) | Expression en surface d'une enzyme dans la therapie genique a base de promedicaments | |
WO1995007995A3 (fr) | Liposomes viraux adeno-associes et methodes associees | |
IL146144A0 (en) | Method and means for producing high titer, safe, recombinant lentivirus vectors | |
IL181695A0 (en) | Methods for cultivating cells and propagating viruses | |
KR960001819B1 (en) | Viral vector coding for a glycoprotein of the virus responsible | |
EP1484409A3 (fr) | Vecteur d'expression comprenant un gène de résistance aux drogues de courte durée | |
AU6415496A (en) | Encapsulated cells producing viral particles | |
WO2005038035A3 (fr) | Procedes de production et d'utilisation de retrovirus pseudotypes in vivo | |
WO2001012235A3 (fr) | Apport cible de gene artificiel | |
EP1070122A4 (fr) | Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale | |
EP0801575A4 (fr) | Vecteurs retroviraux destines a l'expression dans les cellules embryonnaires | |
CA2329510A1 (fr) | Sequences de type promoteur exprimees dans les antheres et les pollens | |
AU5008296A (en) | Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy | |
CA2282394A1 (fr) | Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4 | |
WO2000071078A3 (fr) | Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere | |
AU1814995A (en) | Galanin receptor, nucleic acids, transformed cells and uses thereof | |
AU5465899A (en) | Pseudotyped retroviruses and stable cell lines for their production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998956852 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998956852 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998956852 Country of ref document: EP |